Related Experiment Video

Updated: Oct 17, 2025

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.1K

Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects

Holger Bronger1,2

  • 1Klinik und Poliklinik für Frauenheilkunde, Klinikum rechts der Isar, Technische Universität München, München, Germany.

Geburtshilfe Und Frauenheilkunde
|October 11, 2021
PubMed

Insights

Immune checkpoint blockade (ICB) therapies targeting PD-1/PD-L1 have shown limited success in ovarian cancer due to its immunosuppressive microenvironment. Future research must identify biomarkers and combination strategies to improve ICB efficacy.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immune checkpoint blockade (ICB) targeting PD-1/PD-L1 has transformed cancer treatment, but ovarian cancer shows limited benefit.
  • Ovarian cancer's low mutational burden, poor antigen presentation, and immunosuppressive cells (Tregs, TAMs) hinder ICB response.
  • Clinical trials report low response rates for PD-1/PD-L1 inhibitors in ovarian cancer, despite some long-term survivors.

Purpose of the Study:

  • To review the immune microenvironment of ovarian cancer.
  • To analyze the impact of the immune milieu on ICB effectiveness.
  • To summarize current clinical trial data on ICB in ovarian cancer.

Main Methods:

  • Literature review of immunotherapy in ovarian cancer.
  • Analysis of immune cell infiltration and function in ovarian tumors.
  • Synthesis of clinical trial outcomes for PD-1/PD-L1 inhibitors.

Main Results:

  • Ovarian cancer exhibits an immunosuppressive tumor microenvironment.
  • PD-1/PD-L1 blockade has yielded suboptimal clinical responses in ovarian cancer.
  • Identifying predictive biomarkers and combination therapies is crucial for enhancing ICB efficacy.

Conclusions:

  • Ovarian cancer's immune landscape presents significant challenges for ICB therapy.
  • Further investigation into biomarkers and combination strategies is essential to improve treatment outcomes.
  • Overcoming resistance mechanisms is key to unlocking the potential of ICB in ovarian cancer.
Keywords:
PD-L1immune checkpoint blockadeovarian cancertumour-infiltrating lymphocytes

More Related Videos

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

18.4K
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
741
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
4.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K